go-v.orgdoi

SAT-059 Treatment Of Primary Aldosteronism With The mTORC1 Inhibitor Everolimus

Beckey Trinh, Matthias Hepprich, Matthias Johannes Betz, Thilo Burkard, Claudia Cavelti‐Weder, Eleonora Seelig, Fabian Meienberg, Denise V. Kratschmar, Alex Odermatt, Hall Michael, Marc Yves Donath, Marta M. Swierczynska · Journal of the Endocrine Society · 2019

  • DOI 10.1210/js.2019-sat-059
  • Publisher Endocrine Society
  • Type conference-abstract
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of the Endocrine Society · Endocrine Society · conference-abstract · 2019

Abstract

Background: Primary aldosteronism, characterized by inappropriately high and relatively autonomous aldosterone production, is one of the most frequent causes of secondary hypertension. In most cases, primary aldosteronism results from unilateral or bilateral adrenal hyperplasia and aldosterone-producing adenoma. Depending on the subtype, patient characteristics and preference, treatment comprises unilateral adrenalectomy or mineralocorticoid receptor antagonists. However, these treatments are not always well tolerated or suitable.

Histological studies have shown up-regulation of mTOR activity in the adrenal cortex of primary aldosteronism patients and mTORC1 inhibition decreases aldosterone production in adrenocortical cells. Consistently, we found that treatment of mice with the mTORC1 inhibitor rapamycin decreased plasma aldosterone levels without affecting other adrenal steroid hormones. Therefore, we aimed to evaluate the mTORC1-inhibitor everolimus as an aldosterone-lowering drug in patients with primary aldosteronism.

Methods: In this open-label, proof-of-concept study, we measured plasma aldosterone levels after a standardized, recumbent saline infusion test in 12 primary aldosteronism patients at baseline, following a two-week everolimus treatment (0.75mg twice daily) and after a two-week washout period. To investigate whether everolimus affects other steroid hormone levels, we measured steroid hormone metabolites in a 24-hour urine collected before each saline infusion test. Results: Median post-infusion plasma aldosterone levels after treatment did not differ significantly from baseline (386 pmol/l, IQR 248-495 vs. 312 pmol/l, IQR 245-426; p = 0.677).

However, a marked decrease in aldosterone levels after treatment was observed in four subjects. Their aldosterone levels returned to baseline values after the washout period. This pattern was mirrored by changes in urinary aldosterone/creatinine and tetrahydroaldosterone/creatinine ratios, suggesting that the observed effect was treatment-related. No consistent changes were detected for other steroid metabolites. Conclusion: This is a first in human study on the treatment of primary aldosteronism with the mTORC1 inhibitor everolimus. Overall, we observed a numerical reduction in aldosterone levels after a 2-week treatment which did not reach statistical significance.

However, 4 patients appeared to respond to treatment. Further studies with a larger patient cohort are required to further elucidate the effects of mTORC1 inhibitors in primary aldosteronism and to characterize the differences between potential responders and non-responders.

Open the resolved locator · 10.1210/js.2019-sat-059

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 05:12 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.1210/js.2019-sat-059
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.